摘要
目的分析血清炎症因子水平与乙肝后肝硬化代偿期患者预后的相关性。方法选取2018年5月至2019年5月本院收治的60例乙肝后肝硬化代偿期患者作为研究对象。随访1年后,根据预后情况分为预后不良组(n=22)和预后良好组(n=38)。分析60例乙肝后肝硬化代偿期患者的预后情况;比较两组临床资料及白细胞介素(IL)-6、IL-8、肿瘤坏死因子-α(TNF-α)水平;Logistic回归分析乙肝后肝硬化代偿期患者预后的影响因素。结果60例患者中,预后不良22例,占比36.67%;预后良好38例,占比63.33%。预后不良组血清IL-6、IL-8、TNF-α水平均高于预后良好组,差异有统计学意义(P<0.05)。经Logistic回归分析结果显示,IL-6、IL-8、TNF-α水平升高是乙肝后肝硬化代偿期患者预后不良的影响因素(OR>1,P<0.05)。结论血清IL-6、IL-8、TNF-α水平升高可能增加乙肝后肝硬化代偿期患者预后不良的风险,早期持续性监测血清IL-6、IL-8、TNF-α水平对评估患者预后并指导早期治疗均具有一定的价值。
Objective Correlation between serum inflammatory factor levels and prognosis of patients with compensatory stage of liver cirrhosis after hepatitis B was analysized.Methods 60 patients with compensatory stage of liver cirrhosis after hepatitis B who were admitted to our hospital fromMay 2018 toMay 2019 were selected as the research subjects.After 1 year follow-up,they were divided into poor prognosis group(n=22)and good prognosis group(n=38)according to the prognosis.The prognosis of 60 patients with compensated cirrhosis after hepatitis B was analyzed;the clinical data and levels of interleukin(IL)-6,IL-8 and tumor necrosis factorα(TNF-α)were compared between the two groups;Logistic regression analysis of the prognostic factors of patients with compensated cirrhosis after hepatitis B.Results Among the 60 patients,22 cases had poor prognosis,accounting for 36.67%;38 cases had good prognosis,accounting for 63.33%.The levels of serum IL-6,IL-8 and TNF-αin the poor prognosis group were higher than those in the good prognosis group,and the difference was statistically significant(P<0.05).Logistic regression analysis showed that increased levels of IL-6,IL-8 and TNF-αwere the influencing factors of poor prognosis in patients with post-hepatitis B cirrhosis in compensated stage(OR>1,P<0.05).Conclusion Elevated serum levels of IL-6,IL-8,and TNF-αmay increase the risk of poor prognosis in patients with compensatory stage of liver cirrhosis after hepatitis B,early and continuous monitoring of serum IL-6,IL-8,and TNF-αlevels has a certain value in evaluating the prognosis of patients and guiding early treatment.
作者
彭双福
PENG Shuangfu(Department of Infection,Yingtan People's Hospital,Yingtan,Jiangxi,335000,China)
出处
《当代医学》
2022年第16期164-166,共3页
Contemporary Medicine